The developer of a fast-acting insulin inhaler to treat hyperglycemia in adult diabetics is preparing to install equipment and upgrades to its Danbury plant that could eventually produce the oral inhaler.
MannKind Corp., based in Valencia, Calif., Â says it is committed to making its Afrezza treatment available as soon as final approval comes from the Food and Drug Administration, possibly by year end.
MannKind opened its 252,000-square-foot Danbury production plant in mid-2008 with a $163 million investment. There are 269 workers there and another 275 at Valencia headquarters and a research facilities in Paramus, N.J., according to the Danbury News-Times.
The drug developer said lower research costs stemming from Afrezza helped narrow its second-quarter loss to $42.3 million, or 37 cents a share, from a loss of $55.6 million, or 54 cents a share, in the same quarter last year.
MannKind also is in clinical trial for a multiple myeloma, an incurable cancer of the blood.
The company is owned by billionaire Alfred Mann.
